Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ClearPoint Neuro, Inc.
Report date May 19, 2026 · Filed May 21, 2026
Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,623 |
Reported balance
After 2026-05-19 transaction · row 1
1 source rowRow 1 · 2026-05-19 · Exercise / conversion · Acquired 12,417 · Balance 110,623 F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Exercise / conversion · Disposed 12,417 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234565 · ownership.xml · derivative · entry 2 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234565 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 18:52 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 755 | $9.10 | $6,870.50 |
DisclosureSEC source: 0001193125-26-139783 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,206 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:43 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 502 | $13.68 | $6,867.36 |
DisclosureSEC source: 0001193125-26-002929 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,451 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2025. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 23:06 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 315 | $21.79 | $6,863.85 |
DisclosureSEC source: 0001193125-25-228831 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,949 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:53 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 523 | $11.94 | $6,244.62 |
DisclosureSEC source: 0000950170-25-093132 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,634 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025. Read SEC document |
| May 22, 2025 Filed May 23, 2025 22:12 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077190 · ownership.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,417 Underlying: Common Stock · 12,417 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074543 · ownership.xml · derivative · entry 2 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074543 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:21 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 525 | $11.89 | $6,242.25 |
DisclosureSEC source: 0000950170-25-049818 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,018 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 406 | $15.38 | $6,244.28 |
DisclosureSEC source: 0000950170-25-001287 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,493 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2024. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 557 | $11.21 | $6,243.97 |
DisclosureSEC source: 0001285550-24-000113 · wk-form4_1727900535.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,087 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2024. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 21:21 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,333 | $5.39 | $7,184.87 |
DisclosureSEC source: 0001285550-24-000086 · wk-form4_1719955307.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,530 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 28, 2024. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:25 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 21,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000069 · wk-form4_1715977516.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,093 Underlying: Common Stock · 21,093 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:19 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000057 · wk-form4_1715779184.xml · derivative · entry 2 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,153 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:19 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 17,153 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001285550-24-000057 · wk-form4_1715779184.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:43 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,056 | $6.80 | $7,180.80 |
DisclosureSEC source: 0001285550-24-000042 · wk-form4_1712090587.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,044 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 28, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:56 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,058 | $6.79 | $7,183.82 |
DisclosureSEC source: 0001285550-24-000005 · wk-form4_1704301006.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,988 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 29, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 16:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,434 | $5.01 | $7,184.34 |
DisclosureSEC source: 0001285550-23-000104 · wf-form4_169635125838802.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,930 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 992 | $7.24 | $7,182.08 |
DisclosureSEC source: 0001285550-23-000078 · wf-form4_168859355434556.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,496 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2023. Read SEC document |
| May 25, 2023 Filed May 26, 2023 18:11 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-23-000064 · wf-form4_168512470141759.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 17,153 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:56 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 851 | $8.44 | $7,182.44 |
DisclosureSEC source: 0001285550-23-000037 · wf-form4_168064180220234.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,504 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:58 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 901 | $7.97 | $7,180.97 |
DisclosureSEC source: 0001285550-23-000007 · wf-form4_167287312360999.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,653 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $7.97 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending December 30, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 705 | $10.19 | $7,183.95 |
DisclosureSEC source: 0001285550-22-000062 · wf-form4_166492182952022.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,752 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $10.19 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending September 30, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:37 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 668 | $12.63 | $8,436.84 |
DisclosureSEC source: 0001285550-22-000029 · wf-form4_165713264416431.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,047 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $12.63 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending June 30, 2022. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,179 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001420506-22-001139 · doc4_1009.xml · derivative · entry 2 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,179 Underlying: Common Stock · 6,179 shares Expires 2032-05-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 9,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001420506-22-001139 · doc4_1009.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,379 F1 · price: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:08 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 847 | $9.96 | $8,436.12 |
DisclosureSEC source: 0001171520-22-000237 · eps10157.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,110 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $9.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2022. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 12:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 730 | $11.54 | $8,424.20 |
DisclosureSEC source: 0001171520-22-000015 · doc4_990.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,263 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $11.54 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2021. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:14 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 470 | $17.92 | $8,422.40 |
DisclosureSEC source: 0001420506-21-001360 · doc4_970.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,533 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $17.92 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended October 1, 2021. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 296 | $20.26 | $5,996.96 |
DisclosureSEC source: 0001420506-21-000845 · doc4_938.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,063 F1 · price: 1.These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $20.26 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2021. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:38 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,006 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001171520-21-000265 · ownership.xml · derivative · entry 2 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 Underlying: Common Stock · 6,006 shares Expires 2031-06-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:38 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001171520-21-000265 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,767 F1 · shares: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 322 | $19.57 | $6,301.54 |
DisclosureSEC source: 0001420506-21-000378 · doc4_920.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,764 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 23:37 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 379 | $15.00 | $5,685.00 |
DisclosureSEC source: 0001420506-21-000012 · doc4_896.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,422 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 22:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 996 | $5.71 | $5,687.16 |
DisclosureSEC source: 0001420506-20-001031 · doc4_856.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,063 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 17:32 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,570 | $3.55 | $5,573.50 |
DisclosureSEC source: 0001171520-20-000288 · doc4_816.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,067 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020. Read SEC document |
| June 03, 2020 Filed Jun 17, 2020 20:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001420506-20-000689 · doc4_810.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:12 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,505 | $3.57 | $5,372.85 |
DisclosureSEC source: 0001420506-20-000361 · doc4_794.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,497 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2020. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:04 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,084 | $4.96 | $5,376.64 |
DisclosureSEC source: 0001420506-20-000007 · doc4_780.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,992 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:07 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,226 | $5.15 | $6,313.90 |
DisclosureSEC source: 0001534424-19-000270 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,908 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:07 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,993 | $3.17 | $6,317.81 |
DisclosureSEC source: 0001534424-19-000197 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,682 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.17 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 28, 2019. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:07 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001534424-19-000174 · ownership.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2020 annual meeting of stockholders. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:13 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,006 | $3.15 | $6,318.90 |
DisclosureSEC source: 0001534424-19-000102 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,689 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2019. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 22:13 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 4,294 | $1.47 | $6,312.18 |
DisclosureSEC source: 0001534424-19-000012 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,683 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2018. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:39 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 3,592 | $1.76 | $6,321.92 |
DisclosureSEC source: 0001534424-18-000336 · ownership.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,389 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.76 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 28, 2018. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:06 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,668 | $2.18 | $5,816.24 |
DisclosureSEC source: 0001534424-18-000239 · girin.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,797 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.18 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 29, 2018. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 12:48 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001534424-18-000207 · girin.xml · derivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2019 annual meeting of stockholders. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 20:53 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,696 | $3.13 | $5,308.48 |
DisclosureSEC source: 0001534424-18-000111 · girin.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,129 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. Read SEC document |
| December 29, 2017 Filed Jan 26, 2018 21:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,273 | $2.75 | $6,250.75 |
DisclosureSEC source: 0001534424-18-000028 · girin.xml · nonDerivative · entry 1 Girin Pascal E R · CIK 0001329811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,433 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.75 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 29, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.